$696 Billion is the total value of Versant Venture Management, LLC's 12 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | Sell | CRISPR Therapeutics AG | $307,413,373,000 | +73.5% | 4,183,064 | -0.5% | 44.16% | -9.1% |
| ADVM | Sell | Adverum Biotechnologies, Inc. | $146,241,265,000 | +111.8% | 7,003,892 | -0.9% | 21.01% | +10.9% |
| APRE | New | Aprea Therapeutics, Inc. | $71,907,001,000 | – | 1,854,229 | +100.0% | 10.33% | – |
| AKRO | Sell | Akero Therapeutics, Inc. | $52,717,114,000 | -9.1% | 2,115,454 | -22.7% | 7.57% | -52.4% |
| CRNX | New | Crinetics Pharmaceuticals, Inc. | $35,576,392,000 | – | 2,030,616 | +100.0% | 5.11% | – |
| VCYT | Veracyte, Inc. | $31,220,041,000 | +6.5% | 1,205,407 | 0.0% | 4.48% | -44.2% | |
| GRTS | Gritstone Oncology, Inc. | $20,603,449,000 | +14.1% | 3,102,929 | 0.0% | 2.96% | -40.2% | |
| OCUL | Ocular Therapeutix, Inc. | $18,454,145,000 | +68.3% | 2,215,384 | 0.0% | 2.65% | -11.8% | |
| ISEE | New | IVERIC bio, Inc. | $8,797,036,000 | – | 1,724,909 | +100.0% | 1.26% | – |
| CBAY | CymaBay Therapeutics, Inc. | $1,897,697,000 | +135.8% | 543,753 | 0.0% | 0.27% | +23.5% | |
| CLVS | Clovis Oncology, Inc. | $687,521,000 | +6.1% | 101,855 | 0.0% | 0.10% | -44.4% | |
| EYES | Second Sight Medical Products, Inc. | $550,211,000 | -1.5% | 561,612 | 0.0% | 0.08% | -48.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-07-20
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-03 |
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.